Laporte J P, Fouillard L, Douay L, Eugene-Jolchine I, Isnard F, Stachowiak J, Najman A, Gorin N C
Bone Marrow Transplant Unit, Hopital St Antoine, Paris, France.
Lancet. 1991 Sep 7;338(8767):601-2. doi: 10.1016/0140-6736(91)90609-s.
Five patients with resistant non-Hodgkin lymphoma (NHL) were given granulocyte-macrophage colony-stimulating factor (GM-CSF, 250 micrograms/m2 daily) after the BEAM pretransplant chemotherapy regimen (carmustine 300 mg/m2, etoposide 1.2 g/m2, cytarabine 800 mg/m2, melphalan 140 mg/m2) because persistent lymphoma cell infiltration of the bone marrow precluded autologous bone-marrow transplantation (BMT). In three patients full haemopoietic reconstitution occurred, with similar kinetics to that seen after autologous BMT. The other two patients died without sustained haemopoietic recovery. GM-CSF may replace autologous BMT in highly selected cases of NHL with progressive disease and bone-marrow involvement.
5例难治性非霍奇金淋巴瘤（NHL）患者在接受BEAM预处理化疗方案（卡莫司汀300mg/m²、依托泊苷1.2g/m²、阿糖胞苷800mg/m²、美法仑140mg/m²）后，因骨髓持续存在淋巴瘤细胞浸润而无法进行自体骨髓移植（BMT），给予粒细胞-巨噬细胞集落刺激因子（GM-CSF，每日250μg/m²）。3例患者实现了完全造血重建，其动力学与自体BMT后所见相似。另外2例患者未实现持续造血恢复而死亡。在高度选择的进展期疾病且累及骨髓的NHL病例中，GM-CSF可能替代自体BMT。
